VRXA (Veraxa Biotech Holding AG) YoY EBITDA Growth: -41.30% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRXA Veraxa Biotech Holding AG VRXA
6 GF Score
Price $1.51
! 3 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG YoY EBITDA Growth?

Veraxa Biotech Holding AG VRXA -0.66% 6 YoY EBITDA Growth is -41.30% as of Dec. 2025. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Veraxa Biotech Holding AG's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was -41.30%.

Veraxa Biotech Holding AG's EBITDA per Share for the three months ended in Dec. 2025 was $0.05.

Veraxa Biotech Holding AG YoY EBITDA Growth Related Terms

Veraxa Biotech Holding AG YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG YoY EBITDA Growth Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 0.00 116.79

Veraxa Biotech Holding AG Quarterly Data
Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth 0.00 0.00 4,050.00 -41.30
VRXA
6GF Score
Veraxa Biotech Holding AG VRXA
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Veraxa Biotech Holding AG's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.284-0.131)/ | 0.131 |
=116.79 %

Veraxa Biotech Holding AG's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: . 20 )) / | EBITDA per Share (Q: . 20 )) |
=(0.054-)/ | |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -41.30% mean?
Veraxa Biotech Holding AG (VRXA) has a YoY EBITDA Growth of -41.30% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Veraxa Biotech Holding AG and its competitors.
Is Veraxa Biotech Holding AG's YoY EBITDA Growth too high?
Veraxa Biotech Holding AG's current YoY EBITDA Growth is -41.30%. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's YoY EBITDA Growth compare to KRRO and CNXU?
Veraxa Biotech Holding AG's YoY EBITDA Growth of -41.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current YoY EBITDA Growth is -41.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current YoY EBITDA Growth of -41.30%. The current YoY EBITDA Growth is -41.30%. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current YoY EBITDA Growth is -41.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges J8L0:Germany
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score

Get the complete analysis for VRXA

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.51
Price